Kelleher Financial Advisors Buys 2,456 Shares of Amgen Inc. $AMGN

Kelleher Financial Advisors increased its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 1,158.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,668 shares of the medical research company’s stock after purchasing an additional 2,456 shares during the quarter. Kelleher Financial Advisors’ holdings in Amgen were worth $873,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of AMGN. West Family Investments Inc. lifted its holdings in Amgen by 1.1% during the 3rd quarter. West Family Investments Inc. now owns 2,760 shares of the medical research company’s stock worth $779,000 after buying an additional 30 shares in the last quarter. Viawealth LLC increased its stake in shares of Amgen by 0.4% in the 3rd quarter. Viawealth LLC now owns 7,168 shares of the medical research company’s stock valued at $2,023,000 after buying an additional 30 shares during the period. LOM Asset Management Ltd raised its position in shares of Amgen by 1.2% during the third quarter. LOM Asset Management Ltd now owns 2,554 shares of the medical research company’s stock worth $721,000 after acquiring an additional 30 shares during the last quarter. Sittner & Nelson LLC raised its position in shares of Amgen by 0.4% during the third quarter. Sittner & Nelson LLC now owns 7,276 shares of the medical research company’s stock worth $2,053,000 after acquiring an additional 30 shares during the last quarter. Finally, ORG Partners LLC lifted its stake in shares of Amgen by 0.6% during the fourth quarter. ORG Partners LLC now owns 5,398 shares of the medical research company’s stock valued at $1,767,000 after acquiring an additional 31 shares during the period. Institutional investors and hedge funds own 76.50% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have weighed in on AMGN shares. Rothschild & Co Redburn boosted their price objective on Amgen from $180.00 to $200.00 and gave the stock a “sell” rating in a report on Wednesday, February 18th. Jefferies Financial Group initiated coverage on shares of Amgen in a research note on Tuesday, March 10th. They set a “hold” rating and a $350.00 price target for the company. Wall Street Zen cut shares of Amgen from a “buy” rating to a “hold” rating in a research note on Saturday, February 21st. Piper Sandler upped their target price on shares of Amgen from $381.00 to $432.00 and gave the company an “overweight” rating in a research report on Wednesday, February 18th. Finally, Sanford C. Bernstein downgraded Amgen from an “outperform” rating to a “market perform” rating and set a $335.00 price target on the stock. in a research note on Tuesday, January 20th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, thirteen have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, Amgen has a consensus rating of “Hold” and a consensus target price of $354.60.

Amgen Price Performance

Amgen stock opened at $347.94 on Friday. The company has a market cap of $187.56 billion, a P/E ratio of 24.45, a price-to-earnings-growth ratio of 3.45 and a beta of 0.47. Amgen Inc. has a 1-year low of $261.43 and a 1-year high of $391.29. The company has a fifty day simple moving average of $363.65 and a 200 day simple moving average of $332.77. The company has a current ratio of 1.14, a quick ratio of 0.90 and a debt-to-equity ratio of 5.78.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, topping the consensus estimate of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The firm had revenue of $9.87 billion for the quarter, compared to analysts’ expectations of $9.46 billion. During the same period in the previous year, the firm posted $5.31 EPS. The company’s revenue for the quarter was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Research analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be issued a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a yield of 2.9%. The ex-dividend date is Friday, May 15th. Amgen’s dividend payout ratio is presently 70.84%.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.